tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2021 Sep 24;8(10)
fab468.
doi: 10.1093/ofid/ofab468. eCollection 2021 Oct.
Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals
Joanna Luczkowiak[SUP] 1 [/SUP], Nuria Labiod[SUP] 1 [/SUP], Gonzalo Rivas[SUP] 2 [/SUP], Marta Rolo[SUP] 2 [/SUP], Fátima Lasala[SUP] 1 [/SUP], Jaime Lora-Tamayo[SUP] 3 [/SUP], Mikel Mancheno-Losa[SUP] 3 [/SUP], David Rial[SUP] 2 [/SUP], Alfredo Pérez-Rivilla[SUP] 2 [/SUP], María D Folgueira[SUP] 2 [/SUP], Rafael Delgado[SUP] 1 2 4 [/SUP]
Affiliations
Abstract
Background: The objective of this study was to investigate the neutralizing response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoC) during coronavirus disease 2019 (COVID-19) convalescence and after vaccination.
Methods: COVID-19-convalescent and -naïve individuals were tested for neutralizing activity against SARS-CoV-2 VoC Alpha, Beta, Gamma, and Delta at 1 and 7 months postinfection and 4-6 weeks after BNT162b2 vaccination.
Results: Vaccination induced a high neutralizing response in naïve individuals. Interestingly, vaccination of convalescent patients induced a boosted response that was able to neutralize all VoC at high titers.
Conclusions: Vaccination with BNT162b2 induced high levels of neutralization against SARS-CoV-2 VoC in most patients; this is especially beneficial in COVID-19-convalescent individuals.
Keywords: COVID-19; SARS-CoV-2; neutralizing antibodies; vaccines; variants of concern.
. 2021 Sep 24;8(10)
fab468.doi: 10.1093/ofid/ofab468. eCollection 2021 Oct.
Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals
Joanna Luczkowiak[SUP] 1 [/SUP], Nuria Labiod[SUP] 1 [/SUP], Gonzalo Rivas[SUP] 2 [/SUP], Marta Rolo[SUP] 2 [/SUP], Fátima Lasala[SUP] 1 [/SUP], Jaime Lora-Tamayo[SUP] 3 [/SUP], Mikel Mancheno-Losa[SUP] 3 [/SUP], David Rial[SUP] 2 [/SUP], Alfredo Pérez-Rivilla[SUP] 2 [/SUP], María D Folgueira[SUP] 2 [/SUP], Rafael Delgado[SUP] 1 2 4 [/SUP]
Affiliations
- PMID: 34642637
- PMCID: PMC8500154
- DOI: 10.1093/ofid/ofab468
Abstract
Background: The objective of this study was to investigate the neutralizing response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoC) during coronavirus disease 2019 (COVID-19) convalescence and after vaccination.
Methods: COVID-19-convalescent and -naïve individuals were tested for neutralizing activity against SARS-CoV-2 VoC Alpha, Beta, Gamma, and Delta at 1 and 7 months postinfection and 4-6 weeks after BNT162b2 vaccination.
Results: Vaccination induced a high neutralizing response in naïve individuals. Interestingly, vaccination of convalescent patients induced a boosted response that was able to neutralize all VoC at high titers.
Conclusions: Vaccination with BNT162b2 induced high levels of neutralization against SARS-CoV-2 VoC in most patients; this is especially beneficial in COVID-19-convalescent individuals.
Keywords: COVID-19; SARS-CoV-2; neutralizing antibodies; vaccines; variants of concern.